Trial Profile
Phase II study of MLN518 in patients with metastatic clear cell renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Tandutinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 24 Mar 2010 Actual patient number (10) added as reported by ClinicalTrials.gov.
- 28 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Oct 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.